



Contribution ID: 112

Type: oral presentation

## Cyclotron production of Sc-44 - new radionuclide for PET technique

Thursday 22 September 2011 16:50 (15 minutes)

**Objectives:** Two isotopes of scandium,  $^{47}\text{Sc}$  and  $^{44}\text{Sc}$ , are perspective radionuclides respectively for radiotherapy and diagnostic imaging.  $^{47}\text{Sc}$  decays with the half-life of 3.35 days and maximum  $\beta^-$  energy of 600 keV. It also emits low-energy  $\gamma$ -radiation ( $E_\gamma = 159$  keV) suitable for simultaneous imaging. The other scandium radionuclide,  $^{44}\text{Sc}$  ( $t_{1/2} = 3.92\text{h}$ ) is an ideal  $\beta^+$ -emitter in PET diagnosis. It can be used as an alternative to  $^{68}\text{Ga}$ , because  $^{44}\text{Sc}$  has longer half-life and forms stable radiobioconjugates with a structure similar to  $^{90}\text{Y}$  and  $^{177}\text{Lu}$ , that is important in planning radionuclide therapy [1].  $^{44}\text{Sc}$  can be obtained as a daughter radionuclide of long-lived  $^{44}\text{Ti}$  ( $t_{1/2} = 60.4\text{y}$ ) from  $^{44}\text{Ti}/^{44}\text{Sc}$  generator or can be produced by nuclear reaction  $^{44}\text{Ca}(p, n)^{44}\text{Sc}$  in small cyclotrons. The aim of our work was to find optimal parameters for  $^{44}\text{CaCO}_3$  target irradiation in order to maximize the production of  $^{44}\text{Sc}$  with minimal impurities of the longer half-life  $^{44m}\text{Sc}$  and to develop a simple chemical procedure for separation of  $^{44}\text{Sc}$  from the calcium target.

**Methods:** In the present work, we used highly enriched  $^{44}\text{CaCO}_3$  (Isoflex, Russia). The irradiations have been performed with the Scanditronix MC 40 Cyclotron of the Joint Research Centre (Ispra, Italy). Designed aluminum capsules were filled with 2 mg of dry  $^{44}\text{CaCO}_3$  powder, inserted into a water cooled target holder and were irradiated at different beam proton energies. For each of the irradiation, a Ti foil was used as a proton beam energy monitor. The activity of the different samples were measured with high resolution  $\alpha$ -ray spectrometry.

Longer-lived  $^{46}\text{Sc}$  was used instead of  $^{44}\text{Sc}$  in the separation procedure. The  $\text{CaCO}_3$  target was dissolved in 1 ml of 0.1 M HCl. Then, the solution was passed through a column filled with iminodiacetic resin Chelex-100. After adsorption of  $^{46}\text{Sc}$  the column was washed with 30 ml of 0.01 M HCl and the effluent containing enriched calcium was collected for further irradiations. The  $^{46}\text{Sc}$  was quantitatively eluted with 1 M HCl in the second 0.5 ml fraction.

**Results:** The  $^{44}\text{CaCO}_3$  target was irradiated by protons in the range of 5.5-23 MeV. The analysis of several irradiations indicate that the amount of  $^{44}\text{Sc}$  reached the maximum, with the lowest production (0.16%) of  $^{44m}\text{Sc}$  impurity in the energy range of 9-10 MeV.

$^{46}\text{Sc}$  was separated from the target on iminodiacetic resin with efficiency of more than 95%, eluted in volume of 0.5 ml. The recovery of the calcium target is nearly quantitative. The level of  $\text{Ca}^{2+}$  in  $^{46}\text{Sc}$  fraction is less than  $3 \mu\text{g/ml}$ .

**Conclusions:** The low-energy irradiation of  $^{44}\text{Ca}$  gives opportunity to produce Ci level activities of  $^{44}\text{Sc}$ . The separation process proposed of  $^{44}\text{Sc}$  from the target is simple and fast. The  $^{44}\text{Sc}$  obtained can be used instead of  $^{68}\text{Ga}$  in PET diagnosis and planning radionuclide receptor therapy.

**Research Support:** This work was carried out as a part of the project of the Ministry of Science and Higher Education of Poland DWM/N166/COST/2007 and COST Action D38.

**References:** [1] A.Majkowska, A.Bilewicz, (2011), J.Inorg.Biochem. 105, 313–320.

**Author:** Prof. BILEWICZ, Aleksander (Institute of Nuclear Chemistry and Technology)

**Co-authors:** Ms KASPEREK, Agata (Institute of Nuclear Chemistry and Technology); Dr SIMONELL, Federica (European Commission, Joint Research Centre, Institute for Health and Consumer Protection, Ispra Italy); Ms

CYDZIK, Izabela (European Commission, Joint Research Centre, Institute for Health and Consumer Protection, Ispra Italy); Dr ABBAS, Kamel (European Commission, Joint Research Centre, Institute for Health and Consumer Protection, Ispra Italy); Mr KRAJEWSKI, Seweryn (Institute of Nuclear Chemistry and Technology)

**Presenter:** Prof. BILEWICZ, Aleksander (Institute of Nuclear Chemistry and Technology)

**Session Classification:** Session 12

**Track Classification:** Radiopharmaceuticals Chemistry